179 related articles for article (PubMed ID: 38076873)
1. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Olopade OI; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Davis MB; Martin ML; Bargonetti J
bioRxiv; 2023 Jun; ():. PubMed ID: 38076873
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
4. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
[TBL] [Abstract][Full Text] [Related]
5. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
6. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
Rathkey D; Khanal M; Murai J; Zhang J; Sengupta M; Jiang Q; Morrow B; Evans CN; Chari R; Fetsch P; Chung HJ; Xi L; Roth M; Filie A; Raffeld M; Thomas A; Pommier Y; Hassan R
J Thorac Oncol; 2020 May; 15(5):843-859. PubMed ID: 32004714
[TBL] [Abstract][Full Text] [Related]
7. Loss of Heterozygosity of
Mizrahi AG; Hamad H; Gugenheim A; Nisman B; Kuznetz A; David IB; Gelfend Y; Cohen S; Zick A; Sheva K; Nechushtan H; Peretz T; Meirovitz A
Anticancer Res; 2022 Nov; 42(11):5257-5263. PubMed ID: 36288893
[TBL] [Abstract][Full Text] [Related]
8. Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors.
Guha M; Sobol Z; Martin M; Hemkens M; Sung T; Rubitski E; Spellman R; Finkelstein M; Khan N; Hu W
Int J Toxicol; 2022 Dec; 41(6):442-454. PubMed ID: 35989659
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.
Pai Bellare G; Sankar Patro B
Biochem Pharmacol; 2022 May; 199():115024. PubMed ID: 35367197
[TBL] [Abstract][Full Text] [Related]
10. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
11. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
[TBL] [Abstract][Full Text] [Related]
12. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
15. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.
Qiu WG; Polotskaia A; Xiao G; Di L; Zhao Y; Hu W; Philip J; Hendrickson RC; Bargonetti J
NPJ Breast Cancer; 2017; 3():. PubMed ID: 28232952
[TBL] [Abstract][Full Text] [Related]
16. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Faraoni I; Graziani G
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
Giansanti M; De Gabrieli A; Prete SP; Ottone T; Divona MD; Karimi T; Ciccarone F; Voso MT; Graziani G; Faraoni I
J Pharmacol Exp Ther; 2021 Jun; 377(3):385-397. PubMed ID: 33820831
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
20. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Polotskaia A; Xiao G; Reynoso K; Martin C; Qiu WG; Hendrickson RC; Bargonetti J
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1220-9. PubMed ID: 25733866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]